Welcome to our dedicated page for Galecto SEC filings (Ticker: GLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galecto, Inc. (NASDAQ: GLTO) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures, giving investors structured access to official information about this clinical-stage biopharmaceutical issuer. Galecto files current and periodic reports with the U.S. Securities and Exchange Commission that describe its oncology and liver disease pipeline, capital structure and key corporate events.
For GLTO, Form 8-K filings are particularly important. Recent 8-Ks detail the acquisition of Damora Therapeutics and the resulting expansion into mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms, the related private placement of Series C non-voting convertible preferred stock, and the issuance of warrants under an antibody discovery and option agreement. Other 8-Ks describe executive appointments, inducement equity awards, and stockholder meeting results, providing insight into governance and leadership changes as Galecto advances DMR-001, DMR-002 and GB3226.
Annual and quarterly reports (Forms 10-K and 10-Q, when available) give more detailed views of Galecto’s research and development spending, general and administrative expenses, net losses and cash runway. These filings also summarize the status of key programs such as GB3226, a dual ENL-YEATS and FLT3 inhibitor for AML, and GB1211, a galectin-3 inhibitor for liver cirrhosis and oncology combinations. Investors can review risk factor discussions and management’s commentary on the company’s strategic focus on cancer and liver diseases.
On this page, Stock Titan pairs Galecto’s raw SEC documents with AI-powered summaries that highlight the main points of lengthy filings, helping users quickly identify material items such as mergers, financings, warrant issuances and preferred stock conversions. Real-time updates from EDGAR ensure new GLTO filings appear promptly, while access to insider-related disclosures, when filed on Form 4 or within other reports, can help users monitor equity grants and ownership changes involving directors and officers.
Whether you are analyzing Galecto’s evolving hematology-oncology pipeline, reviewing the terms of its private placements, or tracking its Nasdaq listing-related disclosures, this GLTO filings page offers a focused view of the company’s regulatory record with tools to make complex documents easier to understand.
Galecto, Inc. is conducting an underwritten primary offering of common stock and Series C non-voting convertible preferred stock under its shelf registration. The Series C shares are convertible into common stock at a 1,000-to-1 ratio, subject to a holder‑set ownership cap between 0% and 19.99% of outstanding common shares.
Galecto is a biopharmaceutical company focused on therapies for hematological cancers, including new candidates targeting myeloproliferative neoplasms and acute myeloid leukemia gained through recent asset acquisitions. The company plans to use net proceeds mainly for preclinical studies, clinical trials, manufacturing for its antibody programs, broader research and development, working capital, and general corporate purposes.
Galecto, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer common stock, preferred stock, debt securities, warrants and units from time to time using prospectus supplements.
The filing details Galecto’s strategic shift into hematologic cancers following its stock-for-stock acquisition of Damora Therapeutics and assumption of the Paragon Option Agreement, adding three mutCALR-targeting antibody programs (DMR-001, DMR-002, DMR-003) and the AML candidate GB3226. Galecto plans IND filings for GB3226 in the first quarter of 2026 and for DMR-001, DMR-002 and DMR-003 between 2026 and 2027.
Galecto also highlights a recently completed approximately $285 million private placement of Series C Preferred Stock and an increase in authorized common shares to 500 million, supporting development of its expanded pipeline in myeloproliferative neoplasms and acute myeloid leukemia.
Galecto, Inc. announced major corporate changes centered on leadership and capital structure. The board determined that, effective February 10, 2026, Hans T. Schambye will step down as Chief Executive Officer and President and resign from the board, with no disagreement cited over operations or policies. Subject to a separation agreement, he will receive benefits under his retention agreement and the Executive Separation Benefits Plan, including lump-sum severance and full acceleration of all outstanding equity awards.
The board appointed current Chief Operating Officer Sherwin Sattarzadeh as interim principal executive officer, with his existing offer letter continuing to govern his employment. At a February 9, 2026 special meeting, stockholders approved the issuance of common shares upon conversion of Series B and Series C preferred stock, an increase in authorized common shares from 300,000,000 to 500,000,000, a redomestication from Delaware to the Cayman Islands, and new 2026 equity incentive and employee stock purchase plans. Following automatic conversion of 42,005 shares of Series C preferred into 42,005,000 common shares, the company had approximately 43.6 million common shares outstanding as of February 9, 2026.
Galecto, Inc. reported new equity awards to its Chief Operating Officer, Sherwin Sattarzadeh. On January 5, 2026, he received 190,376 shares of common stock in the form of restricted stock units, granted at a price of $0 per share. These RSUs vest 25% on each anniversary of the grant date over four years, so the award is spread out to encourage continued service.
On the same date, he was also granted a stock option covering 444,209 shares of common stock with an exercise price of $21.82 per share. This option vests 25% on January 5, 2027 and then in equal monthly installments through January 5, 2030, again conditioned on his continued service to Galecto.
Galecto, Inc. filed an initial insider ownership report for its Chief Operating Officer. The Form 3 identifies Sherwin Sattarzadeh as the company’s Chief Operating Officer and a reporting person under insider ownership rules. The filing states in the remarks that no securities are beneficially owned, meaning the officer reported holding no Galecto, Inc. common stock or derivative securities at the time of this initial statement.
Paramora Holding LLC filed a Schedule 13G reporting beneficial ownership of 120,473 shares of Galecto, Inc. common stock, equal to 7.5% of the class based on 1,597,321 shares outstanding as of December 29, 2025. Paramora has sole voting and sole dispositive power over these shares, with no shared voting or dispositive power.
The filing notes additional Galecto Series C Non-Voting Convertible Preferred Stock held by Paramora that could convert into common stock at a rate of 1,000 common shares per preferred share, but these potential shares are excluded from the reported ownership. Conversion is subject to stockholder approval under Nasdaq rules and a 4.99% Beneficial Ownership Limitation, which restricts how much common stock Paramora can hold upon conversion. The filing states the securities are not held for the purpose of changing or influencing control of Galecto.
Galecto, Inc. shareholder Paragon Therapeutics, Inc. reports beneficial ownership of 120,473 shares of Galecto common stock, representing 7.5% of the class. Paragon has sole power to vote and dispose of these shares, with no shared voting or dispositive power.
The 7.5% figure is based on 1,597,321 shares of Galecto common stock outstanding as of December 29, 2025. The filing notes that this stake excludes common shares issuable from Series C Non-Voting Convertible Preferred Stock, which would convert at a rate of 1,000 common shares per preferred share, subject to stockholder approval and a 4.99% Beneficial Ownership Limitation. Paragon certifies that the securities are not held for the purpose of changing or influencing control of Galecto.
Galecto, Inc. reported that it plans to meet with securities analysts, investors and others in connection with the 44th Annual J.P. Morgan Healthcare Conference beginning on January 12, 2026. During these meetings, the company expects to use a corporate slide presentation that is included as Exhibit 99.1, titled “Corporate Presentation (January 2026). The information related to these meetings and the presentation is being furnished under Regulation FD, meaning it is not treated as filed for purposes of the Securities Exchange Act of 1934 and is not subject to the associated liability provisions or automatically incorporated into other securities law filings.
Galecto, Inc. reported new equity awards to Chief Medical Officer Hewes L. Becker. On January 5, 2026, Becker received 264,629 restricted stock units, each representing one share of Galecto common stock at settlement. These RSUs vest 25% on each anniversary of the grant date over four years, conditioned on continued service.
On the same date, Becker was granted a stock option covering 528,603 shares of common stock at an exercise price of $21.82 per share. The option vests 25% on January 5, 2027 and then in equal monthly installments through January 5, 2030, also subject to continued service. Following these grants, Becker directly holds 264,629 shares of common stock and options for 528,603 shares.
Galecto, Inc.’s Chief Medical Officer files an initial ownership report showing no holdings. Hewes L. Becker, the company’s Chief Medical Officer, submitted a Form 3 indicating that no securities of Galecto, Inc. are beneficially owned. The filing confirms his officer role and that this is an individual filing, with a remark explicitly stating that no securities are beneficially owned.